Application of a Tissue-Free Epigenomic Assay to Improve MRD Detection in Previously Treated CRC
Yoshiaki Nakamura, MD, PhD, discusses how a methylation-based circulating tumor DNA assay can enhance minimal residual disease detection and improve prognosis in patients with previously treated stage II-III colorectal cancer.